Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5737_Библиотеки_им_академика_М_И_Перельмана
.pdf
179Functional Specication
Group the functional specications as appropriate for the project. May be divided
by screens, functional areas, user role, high‑level functions vs detailed functions, or
any other way that works for your project.
3.1 <title>
3.1.1 Purpos e/Description
Include a high‑level description and purpose of the specications covered in the
section.
3.1.2 Use Case
Map the functional requirement to one or more use cases mentioned in the Business
Requirements Document. If the use case is not described in detail in the Business
Requirements Document, describe the use case here. This typically includes the ele‑
ment s in the following table.
3.1.3 Mock‑Up
Provide the mock‑up of the functionality or a mock‑up of the entire page.
3.1.4 Functional Requirements
Describe the page level details. These may include any requirements related to
Navigation Menu, Actions, transaction status, verication and validation require‑
ments, etc.
<Use case name>
Primary Personnel(s) < that participate in this use case>
Stakeholders and Interest
< describing other stakeholders>
Trigger
<action that initiates/starts the use case>
Pre‑conditions
<assumed to be true before the rst step>
Post‑conditions
<after the use case is successfully executed >
Main Success Scenario 1. STARTING‑POINT
2. Step
3. Step
4. GOAL‑ACHIEVED>
Extensions If Condition, then Alternative Steps
List any extended steps/ scenarios that occur, other than
the main success scenario.
Priority high, medium or low
Special Requirements
<system related special requirements needed to fulll the
use case>
https://t.me/med1917
180 Basics of Pharmaceutical Manufacturing and Quality Operations
Make sure each specication has a reference number and is explained in the
following format.
4 SYSTEM CONFIGURATIONS
<Provide an overview of all the steps or the set ups required to congure an appli‑
cation/program. Also state the intent or purpose behind each set up or congura‑
tion. Discuss the possible alternatives, customizations, workaround’s, conditions, and
dependencies in a particular conguration. In case of Oracle applications, please list
all applicable BR100’s or Application set up documents>
5 OTHER SYSTEM REQUIREMENTS
<This section is used in contrast with stated functional requirements to highlight the
additional details on the quality related aspects as well as other behavioral aspects
of a system. This section is used to capture the stakeholders’ implicit expectations
about how well the system will work under a given circumstance. Here you can state
the specic SLAs related to system response times (data search and retrieval), perfor‑
mance needs and metrics, latencies in a particular timeframe or during high‑volume
transactions, system failures and recovery management, security levels and acces‑
sibility constraints, data backup and archiving capabilities, legal compliance needs,
etc. The broader denition of the term “system” also includes integrations with all
types of mobile platforms, mobile devices, tablets, and smart phones.>
6 REPORTING REQUIREMENTS
<This section is used to capture the reporting needs, including but not limited to the
scope and format of the report, data elements and contents required on the report,
le types and extraction mechanisms, user base and accessibility levels, frequency
of report extractions, etc. Also provide the mock‑up of the report if needed. If neces‑
sary, create a separate document for reporting requirements.>
7 INTEGRATION REQUIREMENTS
<Identify the integration needs and state all required interfaces with anything exter‑
nal to this solution including hardware, software, and users. Include Architectural
overview diagrams, high‑level data ow diagrams, table structures and schema,
interface protocols, API’s, Error conditions, Error validations and messaging needs,
Auto processing requirements, etc. You can optionally state hardware and software
dependencies, Upgrade requirements, compatibility issues with existing frameworks
and solutions, etc.>
(Data Flow Diagrams, Interface Diagrams–if necessary)
Spec ID Specication Description
Business Rules/Data
Dependency
<Specication Identier> <Short explanation of the
specication>
<Any validation rules or
business rules>
https://t.me/med1917
181Functional Specication
7.1 excePtion hanDling/error rePorting
<This is where you can explain the error conditions/exceptions that normally hap‑
pen in interfaces or cross ow system integrations. Explain the nature of exception,
Error Id, Root cause of the error and also the strategy to handle the scenario. You can
also indicate if there are any concurrent programs designed to automatically handle
the error records or error conditions. State if there are any error reports generated or
notications utilized to alarm the support teams and system Administrators during
the interface failures or outages.>
8 DATA MIGRATION/CONVERSION REQUIREMENTS
<Explain in brief the data conversion plan. Provide full identifying information for
the automated system, application, or situation for which the data conversion plan
applies. Describe briey any assumptions, constraints or risks regarding the data
conversion effort. (Provide details in Section 1.6.)
8.1 Data conversion strategy
<Include the overall strategy for the Data Conversion. This includes how and when
you will perform the conversion–the approach used to extract, transform and load
data during the conversion process, the conversion schedule, and test plan for testing
the converted data.>
8.2 Data conversion PreParation
<Provide details on any prerequisites necessary for the conversion. Discuss the
backup strategy, restoration process in case the conversion fails.>
8.3 Data conversion sPecifications
9 REFERENCES
<List all references to external material used as background information or knowl‑
edge for the FSD. Examples may include a compliancy website, Stanford website,
etc.>
Exception/Error ID Error Cause Solution Strategy
Source
Source Data
Element Target
Target Data
Element
Conversion
Rules Notes
<Source
Location>
<Source Data
Element
Identier >
<Target
Location>
<Target Data
Element Identier>
<Describe
Rules for Data
Conversion>
<Additional
Notes>
https://t.me/med1917
11
Stability Studies,
Stability Indicating, and
Methods Degradates
The stability program ensures product quality, safety, and efcacy meet throughout
the shelf life. This is considered a prerequisite for the acceptance and approval of any
pharmaceutical product. These studies must be conducted and planned following the
guidelines issued by regulated authorities.
Stability testing provides evidence of how a drug substance or product’s quality
varies with time under the inuence of various environmental factors such as temper-
ature, humidity, and light. It also establishes a re-test period for the drug substance or
shelf life for the drug product and recommended storage conditions.
In a stability program, products are kept under certain conditions in a chamber.
This chamber is validated for temperature and humidity.
The stability studies are pulled on certain time points and tested. The documented
stability proves that products are stable up to a certain time under a certain condition.
Stability also provides the expiry of products.
STABILITY
Stability is dened as “The capacity of a drug product to remain within specications
established to ensure its identity, strength, quality, and purity”.
EXPIRY DATE
The date placed on the container/labels of a drug product designates the time during
which a batch of the product is expected to remain within approved stability speci-
cations if stored under dened conditions.
SHELF LIFE
The time interval that a drug product is expected to remain within approved stability
specication if it is stored under the conditions dened on the label in the proposed
container/closure system.
ACCELERATED TESTING
Studies conducted under dened conditions for temperature and humidity are
designed to increase the rate of chemical degradation or physical change of a drug
182
DOI: 10.1201/9781003366393-16
https://t.me/med1917
183Stability Studies, Stability Indicating, and Methods Degradates
substance or drug product by using exaggerated storage conditions as part of the
formal stability studies.
LONG TERM TESTING
Stability studies under the recommended storage conditions for the retest or shelf life
proposed (or approved) for labelling.
BRACKETING
The design of the stability schedule so that at any time point, only the samples on
the extremes (e.g., container size and/or dosage strengths) are tested. The design
assumes that those at the extremes represent the stability of the intermediate condi-
tion samples. Where a range of dosage strengths is to be tested, bracketing designs
may be particularly applicable if the strengths are very closely related in composition
(e.g., tablet range made with different compression weights of a similar basic granu-
lation, or a capsule range made by lling different plug ll weights of the same basic
composition into different size capsule shells). Where a range of sizes of immediate
containers is to be evaluated, bracketing designs may be applicable if the material
composition of the container and type of closure are the same throughout the range.
MATRIXING
The statistical design of a stability schedule so that only a fraction of the total number
of samples are tested at any specied test point. At a subsequent test point, different
sets of samples of the total number would be tested. This design assumes that the
stability of the samples tested represents the stability of all samples. In every case,
all batches must be tested initially and at the end of the long-term testing (at expiry).
The differences in the samples for the same drug product should be identied as,
for example, covering different batches, different strengths, and different sizes of
the same container/closure system and possibly, in some cases, different container/
closure systems. Matrixing can cover reduced testing when more than one variable is
being evaluated, and, hence, the design of the matrix will be dictated by the factors
to be covered and evaluated. This plan works well for those products with moderate
stability and small variability in the stability data. It is desirable to discuss the design
with regulatory authorities in advance and the Matrixing proposal should be submit-
ted in a pre-approval supplement.
ACCELERATED STUDIES
Accelerated studies are tested for up to six months.
Accelerated testing of the drug substance helps identify degradation products,
which can help to establish the degradation pathways and validate the stability using
the analytical procedures used.
Stress testing is likely to be carried out on a single batch of the drug substance. It
should include the effect of temperatures (in 10°C increments (e.g., 50°C, 60°C, etc.)
https://t.me/med1917
184 Basics of Pharmaceutical Manufacturing and Quality Operations
above that for accelerated testing), humidity (e.g., 75% RH or greater) where appro-
priate, oxidation, and photolysis on the drug substance.
Examining degradation products under stress conditions is helpful in establishing
degradation pathways and developing and validating suitable analytical procedures.
However, it may not be necessary to examine specically for certain degradation
products if it has been demonstrated that they are not formed under accelerated or
long-term storage conditions.
Results from these studies can be provided to regulatory authorities to register the
product.
SELECTION OF BATCHES
Data from accelerated stability studies can be provided on at least three primary
batches of the drug substance. The batches should be manufactured to a minimum
pilot scale by the same procedure and using a method of manufacture and procedure
that simulates the nal process to be used for production batches. The quality of the
batches of the drug substance placed on formal stability studies should represent the
quality of the material to be made on a production scale.
CONTAINER CLOSURE SYSTEM
The stability studies should be conducted on the drug substance packaged in a con-
tainer closure system that is the same as the packaging proposed for storage and sale.
TESTING FREQUENCY
For long-term studies, the frequency of testing should be sufcient to establish the
stability prole of the drug substance. For drug substances with a proposed testing
period of at least 12 months, the frequency of testing under the long-term storage
condition should usually be every three months over the rst year, every six months
over the second year, and annually thereafter through the proposed re-test period.
Under the accelerated storage condition, a minimum of three-time points, includ-
ing the initial and nal time points (e.g., zero, three, and six months), from a six-month
study is recommended.
If accelerated stability fails, intermediate storage studies are activated.
When testing under the intermediate storage condition is called for as a result of
signicant change under the accelerated storage condition, a minimum of four time
points, including the initial and nal time points (e.g., 0, 6, 9, 12 months), from a
12-month study is recommended.
STABILITY STORAGE CONDITIONS
The environment into which stability batches are placed for storage is known as Stability
Storage Conditions. The conditions are controlled and monitored to maintain predeter-
mined temperature, relative humidity, and/or light settings within allowable tolerances.
https://t.me/med1917
185Stability Studies, Stability Indicating, and Methods Degradates
A documented plan to monitor and establish how the quality of a nished drug
product may vary over time under the inuence of environmental factors, including
temperature, humidity, and light, is known as a stability program.
Generally, a drug substance should be evaluated under storage conditions (with
appropriate tolerances) that test its thermal stability and, if applicable, its sensitivity
to moisture. The storage conditions and the lengths of studies chosen should be suf-
cient to cover the storage, shipment, and subsequent use.
The long-term testing should cover a minimum of 12 months on at least three
primary batches at the time of submission and should be continued for some time
sufcient to cover the proposed re-test period. Data from the accelerated storage
condition and, if appropriate, from the intermediate storage condition can be used to
evaluate the effect of short-term excursions outside the label storage conditions (such
as might occur during shipping).
STABILITY CHAMBERS
Stability samples are placed in stability chambers. Stability chambers are designed
to maintain certain humidity and temperature.
The typical temperatures and humidity are as follows:
LONG‑TERM STUDIES
25ºC ± 2ºC/60% RH ± 5% RH or 30ºC ± 2 ºC/65% RH ± 5% RH, for 12 months.
INTERMEDIATE STUDIES
30ºC ± 2 ºC/65% RH ± 5% RH, for six months.
Accelerated studies: 40ºC ± 2ºC/75% RH ± 5% RH, for six months
STABILITY COMMITMENT
When available long-term stability data on primary batches do not cover the pro-
posed re-test period granted at the time of approval, a commitment should be made
to continue the stability studies post-approval in order to rmly establish the re-test
period.
Where the submission includes long-term stability data on three production
batches covering the proposed re-test period, a post-approval commitment is con-
sidered unnecessary. Otherwise, one of the following commitments should be
made:
If the submission includes data from stability studies on at least three pro-
duction batches, a commitment should be made to continue these studies
through the proposed re-test period.
If the submission includes data from stability studies on fewer than three pro-
duction batches, a commitment should be made to continue these studies
https://t.me/med1917
186 Basics of Pharmaceutical Manufacturing and Quality Operations
through the proposed re-test period and to place additional production
batches, to a total of at least three, on long term stability studies through the
proposed retest period.
If the submission does not include stability data on production batches, a
commitment should be made to place the rst three production batches on
long-term stability studies through the proposed re-test period.
EVALUATION
The purpose of the stability study is to establish, based on testing a minimum of
three batches of the drug substance and evaluating the stability information (includ-
ing, as appropriate, results of the physical, chemical, biological, and microbiological
tests), a re-test period applicable to all future batches of the drug substance manu-
factured under similar circumstances. The degree of variability of individual batches
affects the condence that a future production batch will remain within specication
throughout the assigned re-test period.
The data may show so little degradation and so little variability that it is appar-
ent from looking at the data that the requested re-test period will be granted. Under
these circumstances, it is normally unnecessary to go through the formal statistical
analysis; providing a justication for the omission should be sufcient.
An approach for analyzing the data on a quantitative attribute expected to change
with time is to determine the time at which the 95% one-sided condence limit for
the mean curve intersects the acceptance criterion. If the analysis shows that the
batch-to-batch variability is small, it is advantageous to combine the data into one
overall estimate. This can be done by rst applying appropriate statistical tests (e.g.,
p values for the level of signicance of rejection of more than 0.25) to the slopes of
the regression lines and zero-time intercepts for the individual batches. If it is inap-
propriate to combine data from several batches, the overall re-test period should be
based on the minimum time a batch can be expected to remain within acceptance
criteria.
The nature of any degradation relationship will determine whether the data should
be transformed for linear regression analysis. Usually, the relationship can be repre-
sented by a linear, quadratic, or cubic function on an arithmetic or logarithmic scale.
Statistical methods should be employed to test the goodness of t of the data on all
batches and combined batches (where appropriate) to the assumed degradation line
or curve.
Limited extrapolating of the real-time data from the long-term storage condition
beyond the observed range to extend the re-test period can be undertaken at approval
time if justied. This justication should be based on what is known about the mech-
anism of degradation, the results of testing under accelerated conditions, the good-
ness of t of any mathematical model, batch size, the existence of supporting stability
data, etc. However, this extrapolation assumes that the same degradation relationship
will continue to apply beyond the observed data.
Any evaluation should cover not only the assay but also the levels of degradation
products and other appropriate attributes.
https://t.me/med1917
187Stability Studies, Stability Indicating, and Methods Degradates
STATEMENTS/LABELING
A storage statement should be established for the labelling in accordance with rel-
evant national/regional requirements. The statement should be based on the stability
evaluation of the drug substance. Where applicable, specic instructions should be
provided, particularly for drug substances that cannot tolerate freezing. The terms
“ambient conditions” or “room temperature” should be avoided.
A re-test period should be derived from the stability information, and a retest date
should be displayed on the container label if appropriate.
STABILITY PROTOCOL
A stability protocol is written and approved by management.
A typical stability protocol consists of the following sections.
• Product and strength.
•
Packaging size
•
Product manufacturer.
•
Number of batches to be placed on study.
• Tests to be performed.
•
Testing frequency.
• Storage conditions.
•
Expiration Date.
• Details of the validated method.
•
Acceptable/approved limits for each test.
STABILITY‑INDICATING METHOD
A stability-indicating method (SIM method) can be dened as a “Validated quantita-
tive analytical method that can detect the change with time in the chemical, physical
or microbiological properties of the drug substance and drug products are specic
so that the content of active ingredients and degradation products can be accurately
measured without interference”.
When analyzing a fresh product for release the product is fresh. With a period, the
product starts to degrade. The active drug starts to convert into related compounds.
So the SIM method must be capable of analyzing those degrades. Those compounds
must be identied, their toxicity must be evaluated, and the limit of those related
compounds must be specied.
The product is treated to some drastic conditions to break the active in related
compounds.
This process is called force degradation or stress studies.
FORCE DEGRADATION
Forced degradation/stress testing is dened as “the stability testing of the drug
substance and drug product under conditions exceeding those used for accelerated
https://t.me/med1917
188 Basics of Pharmaceutical Manufacturing and Quality Operations
stability testing”. Degradation can be achieved by exposing the drug, for an extended
period, to extremes of pH (HCl or NaOH solutions of different strengths), at elevated
temperature, to hydrogen peroxide at room temperature, to UV light, and to dry heat
(in an oven) to achieve degradation to the extent of 5%–20%. Generally, trial and
error experimentation are used during these experiments.
QUESTIONS AND ANSWERS
1. Dene stability?
Answer: Stability is dened as “The capacity of a drug product to remain
within specications established to ensure its identity, strength, quality, and
pur i t y”.
2. What is the expiry date?
Answer: The date placed on the container/labels of a drug product desig-
nates the time during which a batch of the product is expected to remain
within approved stability specications if stored under dened conditions.
3. What are accelerated studies?
Answer: Studies conducted under dened conditions for temperature and
humidity are designed to increase the rate of chemical degradation or physi-
cal change of a drug substance or drug product by using exaggerated storage
conditions as part of the formal stability studies.
4. What are the storage conditions for long term, intermediate and accel‑
erated studies?
Answer: Long-term studies: 25ºC ± 2ºC/60% RH ± 5% RH or 30ºC ± 2 ºC/
65% RH ± 5% RH, for 12 months.
Intermediate studies: 30ºC ± 2 ºC/65% RH ± 5% RH, for six months.
Accelerated studies: 40ºC ± 2 ºC/75% RH ± 5% RH, for six months
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана